NEW YORK (
CHANGE IN RATINGS
(AAPL - Get Report)
was upgraded at Robert Baird to outperform from neutral. $620 price target. 2014 holds more promise for the company, Robert Baird said.
(DLA - Get Report)
was downgraded to hold at TheStreet Ratings.
was downgraded at Bank of America/Merrill Lynch to underperform from buy. Valuation call, based on a $42 price target, Bank of America/Merrill said.
was downgraded at Keybanc to hold from buy. Estimates were also cut, as the company lacks near-term catalysts, Keybanc said.
(KBR - Get Report)
was upgraded to buy at TheStreet Ratings.
was upgraded at Goldman Sachs to buy. $45 price target. Stock has pulled back to an attractive entry point and growth is not likely to slow significantly, Goldman Sachs said.
was downgraded at FIG Partners to market perform. $16 price target. Company is facing higher costs, FIG Partners said.
was upgraded at Sterne Agee to buy. Company is cutting costs, and the earnings bar has been reset to a more reasonable level, Sterne Agee said.
was downgraded at Credit Suisse to neutral from outperform. Valuation call, based on a $23 price target, Credit Suisse said.
was downgraded at Sterne Agee to neutral from buy. Valuation call, as the stock moved through the $28 price target, Sterne Agee said.
Stock Comments/EPS Changes
Apple numbers were raised at J.P. Morgan. Shares are now seen reaching $600. Estimates were also increased through 2014 on strong quarterly results. Overweight rating.
Apple numbers were raised at Barclays. Shares are now seen reaching $585. Estimates were also increased on strong quarterly results, Barclays said. Overweight rating.
(HLS - Get Report)
price target, estimates were raised at UBS. Healthsouth lifted its estimates across the board. Higher revenue and favorable workers comp reversal drive upside, UBS said. $35.50 price target and neutral rating.
estimates, price target were lifted at UBS. The company continues to outgrow the industry and return cash to shareholders, UBS said. $34 price target and buy rating.